NEW YORK (GenomeWeb) – The Broad Institute has scored an early, decisive blow in the CRISPR patent battle against the University of California.

On Wednesday, the three-judge panel from the Patent Trial and Appeal Board (PTAB) hearing the interference case issued a judgement of no interference-in-fact, stopping UC's bid for intellectual property underpinning the most lucrative applications of genome editing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.